Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06465810 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06465810 · ClinicalTrials.gov record · last posted 2026-08-19

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Name: Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis — clinical trial record (NCT06465810)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MaesTTRo

StatusRecruiting

PhaseNot specified

SponsorAstraZeneca

Started2024-06-25

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

Protocol amendment history 5 changes detected by DataLookout

2026-08-20

Trial sites expanded: 82 → 89 locations

2026-07-29

Trial sites expanded: 74 → 82 locations

2026-06-24

Trial sites expanded: 67 → 74 locations

2026-05-27

Trial sites expanded: 60 → 67 locations

2026-05-06

Trial sites expanded: 53 → 60 locations

Trial Details

NCT Number	NCT06465810
Lead Sponsor	AstraZeneca Collaborators: ICON plc
Conditions	Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
Enrollment	1,850 participants
Start Date	2024-06-25
Primary Completion	2031-12-29 (estimated)
Study Completion	2031-12-29 (estimated)
Updated on ClinicalTrials.gov	2026-08-19